Literature DB >> 16964828

Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.

Anne Maagaard1, Mona Holberg-Petersen, Gittan Kollberg, Anders Oldfors, Leiv Sandvik, Johan N Bruun.   

Abstract

OBJECTIVES: Most data on mitochondrial toxicity have been derived from peripheral blood mononuclear cells (PBMCs). However, whether mitochondrial DNA (mtDNA) content in PBMCs reflects the mitochondrial state in tissues remains elusive. We report herein on mitochondrial toxicity in skeletal muscle in HIV-infected patients naive to antiretroviral treatment (ART [HIV+ART-naive]; n = 10) patients exposed to nucleoside reverse transcriptase inhibitors (NRTIs [HIV+NRTI+]; n = 24) and healthy controls (n = 11), and compare these tissue data with mtDNA in PBMCs.
METHODS: Muscle biopsies were examined for (i) mtDNA and nuclear DNA (nDNA) content using TaqMan real-time PCR system, (ii) mtDNA deletions using long expand PCR with subsequent gel electrophoresis, and (iii) mitochondrial myopathy expressed as cytochrome c oxidase (COX)-deficient muscle fibres.
RESULTS: The mt/n DNA ratio in muscle from HIV+NRTI+ patients was reduced compared with HIV-negative controls (P = 0.028). Moreover, mtDNA deletions were more frequent in HIV+NRTI+ patients than in both HIV-negative controls (P = 0.009) and HIV+ART-naive patients (P = 0.005). HIV+NRTI+ also tended to have more COX-deficient fibres than HIV-negative controls (P = 0.076). COX-deficient fibres were positively correlated with mtDNA deletions in HIV+NRTI+ patients (r = 0.83, P < 0.001). Patients with current use of didanosine (ddl) had more frequent mtDNA deletions and COX-deficient fibres than HIV+NRTI+ not on current treatment with ddl. It should be noted that mitochondrial alterations were not correlated with mtDNA/cell in PBMCs in any group.
CONCLUSIONS: In skeletal muscle, HIV+NRTI+ had a reduced mt/n DNA ratio, more frequent mtDNA deletions and possibly more COX-deficient muscle fibres than HIV-negative controls. However, the mtDNA/cell in peripheral blood was decreased in both HIV+NRTI+ and HIV+ART-naive patients. Thus, mtDNA in peripheral blood may not be a relevant marker of mitochondrial toxicity in organ-specific tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964828

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  19 in total

1.  Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.

Authors:  Marilyn J Crain; Miriam C Chernoff; James M Oleske; Susan B Brogly; Kathleen M Malee; Peggy R Borum; William A Meyer; Wendy G Mitchell; John H Moye; Heather M Ford-Chatterton; Russell B Van Dyke; George R Seage Iii
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  HIV and mitochondria: more than just drug toxicity.

Authors:  Todd Hulgan; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

3.  Antiretroviral neurotoxicity.

Authors:  Kevin Robertson; Jeff Liner; Rick B Meeker
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

4.  HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue.

Authors:  Caryn G Morse; Joachim G Voss; Goran Rakocevic; Mary McLaughlin; Carol L Vinton; Charles Huber; Xiaojun Hu; Jun Yang; Da Wei Huang; Carolea Logun; Robert L Danner; Zoila G Rangel; Peter J Munson; Jan M Orenstein; Elisabeth J Rushing; Richard A Lempicki; Marinos C Dalakas; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

5.  Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.

Authors:  Todd Hulgan; Rebecca T Levinson; Mariana Gerschenson; Nittaya Phanuphak; Jintanat Ananworanich; Nipat Teeratakulpisarm; Tanate Jadwattanakul; Daniel E LiButti; Heidi Fink; Justin C McArthur; Gigi J Ebenezer; Peter Hauer; Deborah Murdock; Cecilia M Shikuma; David C Samuels
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

6.  Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.

Authors:  Andrea L Ciaranello; George R Seage; Kenneth A Freedberg; Milton C Weinstein; Shahin Lockman; Rochelle P Walensky
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

7.  Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.

Authors:  Grace M Aldrovandi; Clara Chu; William T Shearer; Daner Li; Jan Walter; Bruce Thompson; Kenneth McIntosh; Marc Foca; William A Meyer; Belinda F Ha; Kenneth C Rich; Jack Moye
Journal:  Pediatrics       Date:  2009-11-23       Impact factor: 7.124

8.  Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.

Authors:  Salina M Torres; Dale M Walker; Consuelo L McCash; Meghan M Carter; Jessica Ming; Edmund M Cordova; Rachel M Pons; Dennis L Cook; Steven K Seilkop; William C Copeland; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-01       Impact factor: 3.216

Review 9.  Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants.

Authors:  Jennifer Jao; Elaine J Abrams
Journal:  Pediatr Infect Dis J       Date:  2014-07       Impact factor: 2.129

10.  Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV.

Authors:  Birgitte Lindegaard; Thine Hvid; Thomas Grøndahl; Christian Frosig; Jan Gerstoft; Pernille Hojman; Bente Klarlund Pedersen
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.